Growth Hormone Deficiency Market 2022
Growth Hormone Deficiency (GHD) is a rare type of disorder where the pituitary gland produces an insufficient secretion of growth hormone in the body. GHD can be congenital or developed in a later stage.
Global Growth Hormone Deficiency Market is expected to have a market value of USD 5,243.3 Million by 2027.
Major Key Players:
MRFR recognizes the following companies as the Key Players in the Global Growth Hormone Deficiency Market— Novo Nordisk A/S, Eli Lily and Company, Novartis AG, and Merck KGaA, and Pfizer.
Major Key Players:
MRFR recognizes the following companies as the Key Players in the Global Growth Hormone Deficiency Market— Novo Nordisk A/S, Eli Lily and Company, Novartis AG, and Merck KGaA, and Pfizer.
Access Full Report Details and Order this Premium Report @ https://www.marketresearchfuture.com/reports/growth-hormone-deficiency-market-10430
Segment Analysis
Global Growth Hormone Deficiency Market is classified into a brand such as Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and others. In addition, the global Growth Hormone Deficiency Market, by application, is segmented into pediatric growth hormone deficiency, Turner syndrome, Idiopathic Short Stature (ISS), small for gestational age, adult growth hormone deficiency, Prader-Willi syndrome, and others. By route of administration, the market is segmented into subcutaneous, intravenous, and intramuscular. The global growth hormone market is segmented by the distribution channel into hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies.
Regional Analysis
Global Human Growth Hormone Deficiency Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Rest of the World.
The Americas is classified into North America. North America is further categorized into the US Canada and Latin America. The Growth Hormone Deficiency Market in the US is expected to hold a major share owing to the growing prevalence of growth hormone deficiency and Turner syndrome, affordability of costly hormonal therapy, and the presence of a well-established healthcare sector.
The European Growth Hormone Deficiency Market is categorized into Germany, the UK, France, Italy, Spain, and the rest of Europe. The European market is expected to be the second-largest Growth Hormone Deficiency Market. This is attributed to the rising occurrences of growth hormone deficiencies, increasing preference for growth hormones in the treatment of Idiopathic Short Stature (ISS), and rising government expenditure for the healthcare sector. According to the data suggested by the Eurostat, it is observed that among the EU member states, healthcare expenditure in France and Germany was equivalent to 11.3% of the GDP in 2017, a larger share than any other EU member state. The next highest ratio was of Sweden (11.0%).
Asia-Pacific is anticipated to be the fastest-growing market owing to the growing healthcare expenditure and the presence of a large patient pool. Growing investments in the region due to increasing demand are expected to contribute to the market growth. For instance, in March 2017, Novo Nordisk initiated a phase 3 clinical trial of somapacitan (NNC0195-0092) for Adult Growth Hormone Deficiency (AGHD) in Japan. Additionally, the rising awareness about the efficiency of growth hormone therapy in short stature is likely to increase the demand for growth hormone products in this region.
The Middle East and Africa region includes the Middle East Africa. Increasing healthcare expenditure, rising investments by major market players, and growing patient pool in this region are attributing to the market growth. For instance, according to the International Trade Administration, health expenditure in the UAE was USD 17 billion in 2017 and is likely to reach USD 21.3 billion by 2022.
Related Reports:
NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and wherever required we will be considering Covid19 Footprints for Better Analysis of Market and Industries. Cordially get in Touch for More Details.
About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans conducts meet with the industry experts and industrial visits for its research analyst members.
Contact Us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 646 845 9312
